Abatacept as an option therapy in difficult to treat psoriatic arthritis

Rheumatology International

Volumn 30, Issue 6, 2010, Pages 849-850

  Vieira, Francisco José Fernandes ^a   Callado, Maria Roseli Monteiro ^a,b   Vieira, Walber Pinto ^a  

^a General Hospital of Fortaleza   (Brazil)

^b NONE   (Brazil)

Author keywords

Abatacept; Psoriatic arthritis

Indexed keywords

ABATACEPT; ALANINE AMINOTRANSFERASE; ANTIINFLAMMATORY AGENT; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; ISONIAZID; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; ARTHRITIS; ARTICLE; ASTHENIA; CASE REPORT; CLINICAL FEATURE; DRUG DOSE INCREASE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOOT EDEMA; HEEL PAIN; HEPATITIS; HUMAN; HUMAN TISSUE; JOINT BIOPSY; JOINT RADIOGRAPHY; KNEE ARTHROSCOPY; LIVER TOXICITY; OSTEOSCLEROSIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SACROILIAC JOINT; SIDE EFFECT; SKIN TUBERCULOSIS; SYNOVITIS; URINE COLOR; VISUAL ANALOG SCALE;

ARTHRITIS, PSORIATIC; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; HEPATITIS; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; ISONIAZID; ISOXAZOLES; JOINTS; LEG; METHOTREXATE; MIDDLE AGED; NUCLEIC ACID SYNTHESIS INHIBITORS; SKIN; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951025652     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-1041-1     Document Type: Article

References (10)

1. Fitzgerald O (2008) Psoriatic arthritis. In: Firestein GS, Budd RC, Harris ED Jr, McInnes IB, Ruddy S, Sergent JS (eds) Kelley's textbook of rheumatology. Available via DIALOG. http://www. mdconsult.com/das/book/body/ 132831804-2/0/1807/528.html. Accessed 21 Apr 2009
2. Ritchlin C (2008) Psoriatic arthritis: pathology and pathogenesis. In: Klippel JH, Stone JH, CroVord LJ, White PH (eds) Primer on the rheumatic diseases. Springer Science, New York, pp 178-184
3. Jones G, Crotty M, Brooks P (2008) Intervenciones para el tratamiento de la artritis psoriásica (Cochrane Review). In: La Biblioteca Cochrane Plus, Issue 3. Available via DIALOG. http://www. update-software.com/ abstractsES/AB000212-ES.htm. Accessed 21 Apr 2009
4. Nash P, Clegg DO (2005) Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 64(Suppl II):ii74-ii77. doi:10.1136/ard.2004. 030783 (Pubitemid 40288528)
5. Gartehner G, Hansen RA, Thieda P, Jonas B, Lohr KN, Carey T (2005) Drug class review on target immune modulators. Available via DIALOG. http://www.ohsu.edu/drugeffectiveness. Accessed 1 Dec 2008
6. Baker H, Ryan TJ (1968) Generalized pustular psoriasis: a clinical and epidemiological study of 104 cases. Br J Dermatol 80:771-793. doi:10.1111/j.1365-2133.1968.tb11947.x
7. Turkiewicz AM, Moreland LW (2007) Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum 56:1051-1066. doi:10.1002/art.22489 (Pubitemid 46613729)
8. Kuek A, Hazleman BL, Ostör AJ (2007) Immune-mediated inXammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 83(978):251-260. doi:10.1136/ pgmj.2006.052688
9. Nakayama Y, Shimizu Y, Hirano K, Ebata K, Minemura M, Watanabe A, Sugiyama T (2005) CTLA-4Ig suppresses liver injury by inhibiting acquired immune responses in a mouse model of fulminant hepatitis. Hepatology 42(4):915-924. doi:10.1002/ hep.20872
10. Westhovens R, Verschueren P (2008) Translating co-stimulation blockade into clinical practice. Arthritis Res Ther 10(Suppl 1):S4. doi:10.1186/ar2415